Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Senesco Technologies has initiated preclinical lab studies on multiple myeloma at Mayo Clinic that will further test the ability of its Factor 5A gene technology to up-regulate apoptosis of cancer cells.
Subscribe to our email newsletter
Additionally, the studies will evaluate delivery molecules for encapsulation of Factor 5A to enhance the time the gene will circulate in the bloodstream before clearance by the body.
The data gathered from these animal experiments, together with the results of other Factor 5A studies, will be reviewed to determine its sufficiency for submission of a protocol to Mayo Clinic for human studies and to FDA for an investigational new drug application.